Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?
- PMID: 31198545
- PMCID: PMC6543953
- DOI: 10.1093/ckj/sfy062
Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?
Abstract
Parathyroid glands consist primarily of chief cells. In some cases, the proportion of parathyroid oxyphil cells increases in patients with chronic kidney disease. We describe a case of secondary hyperparathyroidism (SHPT) in a patient treated with haemodialysis who initially received large doses of vitamin D and calcium (Ca) supplements, as well as high doses of cinacalcet hydrochloride (C-HCl), but without any effect on parathyroid hormone levels. Following a successful parathyroidectomy, histopathological examination revealed that two of the parathyroid glands consisted of 40% of oxyphil cells. Oxyphil cells have significantly more Ca-sensing receptors (CaSRs) than chief cells, suggesting that CaSRs are involved in the transdifferentiation of chief cells to oxyphil cells. C-HCl treatment leads to a significant increase in parathyroid oxyphil cell content. This case suggests that C-HCl may induce specific phenotypic alterations in hyperplastic parathyroid glands in patients with severe SHPT.
Keywords: calcimimetic; calcium-sensing receptor; chronic kidney disease; haemodialysis; secondary hyperparathyroidism.
Figures
Similar articles
-
Relationship between parathyroid oxyphil cell proportion and clinical characteristics of patients with chronic kidney disease.Int Urol Nephrol. 2020 Jan;52(1):155-159. doi: 10.1007/s11255-019-02330-y. Epub 2019 Nov 4. Int Urol Nephrol. 2020. PMID: 31686279
-
Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.Kidney Int. 2017 Nov;92(5):1217-1222. doi: 10.1016/j.kint.2017.05.003. Epub 2017 Jul 24. Kidney Int. 2017. PMID: 28750928
-
Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.J Clin Pathol. 2011 Sep;64(9):756-60. doi: 10.1136/jclinpath-2011-200100. Epub 2011 May 12. J Clin Pathol. 2011. PMID: 21565858
-
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.J Ren Nutr. 2006 Jul;16(3):253-8. doi: 10.1053/j.jrn.2006.04.010. J Ren Nutr. 2006. PMID: 16825031 Review.
-
[Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl].Clin Calcium. 2009 Apr;19(4):545-50. Clin Calcium. 2009. PMID: 19329834 Review. Japanese.
Cited by
-
Integrated transcriptomic and proteomic analyses for the characterization of parathyroid oxyphil cells in uremic patients.Amino Acids. 2022 May;54(5):749-763. doi: 10.1007/s00726-022-03126-8. Epub 2022 Mar 29. Amino Acids. 2022. PMID: 35348903
-
Relationship between parathyroid oxyphil cell proportion and clinical characteristics of patients with chronic kidney disease.Int Urol Nephrol. 2020 Jan;52(1):155-159. doi: 10.1007/s11255-019-02330-y. Epub 2019 Nov 4. Int Urol Nephrol. 2020. PMID: 31686279
References
-
- Chertow GM, Plone M, Dillon MA. et al. Hyperparathyroidism and dialysis vintage. Clin Nephrol 2000; 54: 295–300 - PubMed
-
- National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1–S201 - PubMed
-
- Ketteler M, Block GA, Evenepoel P. et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int 2017; 92: 26–36 - PubMed
-
- Urena P, Frazao JM.. Calcimimetic agents: review and perspectives. Kidney Int 2003; 63(Suppl 85): S91–S96 - PubMed
-
- Urena P, Fouque D, Brunet P. et al. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice – the ECHO observational study: French experience. Nephrol Ther 2012; 8: 527–533 - PubMed
LinkOut - more resources
Full Text Sources